Safety and Efficacy of Extended-Release Niacin for the Treatment of Dyslipidaemia in Patients with HIV Infection: Aids Clinical Trials Group Study A5148

Background Dyslipidaemia is very common in patients with HIV infection, but current therapies are often suboptimal. Since niacin may cause insulin resistance and hepatotoxicity, it has generally been avoided in this setting. Methods Non-diabetic male subjects ( n =33) who had well-controlled HIV infection on antiretroviral therapy, fasting triglycerides ≥2.26 mmol/l and non-high density lipoprotein cholesterol (non-HDL-C) ≥4.66 mmol/l received escalating doses of extended-release niacin (ERN) up to 2,000 mg nightly for up to 44 weeks. Results Fourteen subjects (42%) had pre-diabetes at entry. Twenty-three subjects (70%) received the maximum dose, eight (24%) received 1,500 mg. Niacin was well-tolerated. Only four subjects (12%) discontinued study treatment. There were small increases in fasting glycaemia and insulin resistance estimated by the homeostasis model assessment, but insulin resistance measures from the 2-h oral glucose tolerance test only transiently worsened. No subject developed persistent fasting hyperglycaemia; one had persistently elevated 2-h glucose >11.1 mmol/l. There were no significant changes in serum transaminases or uric acid. At week 48, the median change in fasting lipid levels in mmol/l (interquartile range) were: total cholesterol -0.21 (-1.35, -0.05), HDL-C +0.013 (-0.03,+0.28), non-HDL-C -0.49 (-1.37, +0.08) and triglycerides -1.73 (-3.68, -0.72). Favourable changes in large HDL and large very low density lipoprotein particle concentration were observed by nuclear magnetic resonance spectroscopy. Conclusions ERN in doses up to 2,000 mg daily was safe, well-tolerated and efficacious in HIV-infected subjects with atherogenic dyslipidaemia. Increases in glycaemia and insulin resistance tended to be transient.

[1]  W. K. Henry,et al.  A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. , 2005, AIDS research and human retroviruses.

[2]  L. Carlson,et al.  Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review , 2005, Journal of internal medicine.

[3]  Stephen R Cole,et al.  Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. , 2005, Archives of internal medicine.

[4]  S. Hammer,et al.  C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s , 2004, AIDS.

[5]  K. Yarasheski,et al.  Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Stein,et al.  Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors , 2004 .

[7]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[8]  Rodolphe Thiébaut,et al.  Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .

[9]  W. K. Henry,et al.  Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Capuzzi,et al.  Effects of extended-release niacin on lipoprotein subclass distribution. , 2003, The American journal of cardiology.

[11]  R. Greenblatt,et al.  Protease Inhibitor Use and the Incidence of Diabetes Mellitus in a Large Cohort of HIV‐Infected Women , 2003, Journal of acquired immune deficiency syndromes.

[12]  J. Stein.  Dyslipidemia in the era of HIV protease inhibitors. , 2003, Progress in cardiovascular diseases.

[13]  S. Mauss,et al.  Differentiating hyperlipidaemia associated with antiretroviral therapy , 2003, AIDS.

[14]  Dannae Brown,et al.  A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia , 2002, AIDS.

[15]  Amalio Telenti,et al.  Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. , 2002, AIDS.

[16]  S. Grundy,et al.  Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. , 2002, Archives of internal medicine.

[17]  Alice Arnold,et al.  Nuclear Magnetic Resonance Spectroscopy of Lipoproteins and Risk of Coronary Heart Disease in the Cardiovascular Health Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[18]  C. Fichtenbaum,et al.  Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 , 2002, AIDS.

[19]  J. Otvos,et al.  Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. , 2002, Clinical laboratory.

[20]  L. Calza,et al.  Use of Fibrates in the Management of Hyperlipidemia in HIV-Infected Patients Receiving HAART , 2002, Infection.

[21]  B. Gazzard,et al.  Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy , 2001, AIDS.

[22]  P. McBride,et al.  Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction , 2001, Circulation.

[23]  T. Buchanan,et al.  Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. , 2001 .

[24]  Nader Rifai,et al.  Handbook of Lipoprotein Testing , 2001 .

[25]  R. D'Agostino,et al.  Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[27]  D. Hunninghake,et al.  Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. , 2000, JAMA.

[28]  A. Goldberg,et al.  Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. , 2000, The American journal of cardiology.

[29]  M. Matsuda,et al.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.

[30]  F. Goebel,et al.  Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV‐1‐infected patients , 1998, AIDS.

[31]  C. Osmond,et al.  Understanding Oral Glucose Tolerance: Comparison of Glucose or Insulin Measurements During the Oral Glucose Tolerance Test with Specific Measurements of Insulin Resistance and Insulin Secretion , 1994, Diabetic medicine : a journal of the British Diabetic Association.

[32]  J. D. Proctor,et al.  A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. , 1994, JAMA.

[33]  Jeani Chang,et al.  Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. , 1993, The American journal of medicine.

[34]  T. A. Dalton,et al.  Hepatotoxicity associated with sustained-release niacin. , 1992, The American journal of medicine.

[35]  K. Feingold,et al.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1992, The Journal of clinical endocrinology and metabolism.

[36]  Jack Wang,et al.  Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome , 1991 .

[37]  J. Wang,et al.  Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. , 1991, The American journal of medicine.

[38]  S. Grundy,et al.  Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. , 1990, JAMA.

[39]  R. Bergman,et al.  Increased β-Cell Secretory Capacity as Mechanism for Islet Adaptation to Nicotinic Acid-Induced Insulin Resistance , 1989, Diabetes.

[40]  D A Armbruster,et al.  Fructosamine: structure, analysis, and clinical usefulness. , 1987, Clinical chemistry.

[41]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.